Clinical Trials Logo

Filter by:
NCT ID: NCT04173273 Recruiting - Crohn's Disease Clinical Trials

A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease

CULTIVATE
Start date: January 6, 2020
Phase: Phase 3
Study type: Interventional

This is a Phase 2/3 study that comprises 5 substudies designed to evaluate the efficacy, safety, and tolerability of oral etrasimod as therapy in adult participants with moderately to severely active Crohn's disease (CD) who are refractory or intolerant to at least 1 of the current therapies for CD (ie, corticosteroids, immunosuppressants, or biologics). The overall duration of this study is up to 282 weeks, inclusive of the Screening Period, Treatment Period of up to 274 weeks (Induction, Extension or Maintenance, and Long-term Extension Periods), and the 4-Week Follow-Up Period for safety assessment.

NCT ID: NCT04173195 Completed - Chemotherapy Effect Clinical Trials

Comfort Talk (CT) During Outpatient Chemotherapy

Start date: September 23, 2019
Phase: N/A
Study type: Interventional

Emotional support and physical comfort are two important components of the patient experience at the oncology outpatient clinic. However, current practices do not seem optimal for meeting the psychosocial needs expressed by patients during chemotherapy treatments. Comfort talk (CT) is a simple, inexpensive intervention that could maximize the feeling of safety and comfort during chemotherapy. Identifying interventions that are interdisciplinary and that can enhance the outpatient patient experience will facilitate access to quality oncology care.

NCT ID: NCT04172740 Completed - Skin Quality Clinical Trials

RADIESSE Injection in Perioral and Marionette Lines

Start date: November 13, 2019
Phase: N/A
Study type: Interventional

Following treatment with Radiesse, many patients mention an improvement in skin texture This observation is independent from the improvement observed on their facial shape. There is therefore a need to identify and quantify changes in skin parameters following treatment with Radiesse

NCT ID: NCT04172688 Completed - Obesity Clinical Trials

Effect of Prebiotics on Function and Pain in Patients With Osteoarthritis and Obesity

Start date: November 18, 2018
Phase: N/A
Study type: Interventional

The purpose of the present study is to determine if prebiotic supplementation can, through changes in the intestinal gut microbiota, lead to improvements in knee function and physical performance and reduce knee pain in adults with obesity and idiopathic metabolic knee osteoarthritis. We hypothesize that prebiotics will reduce systemic and local (knee joint) inflammation, thus improving knee function, lower pain medication use, and enhance performance of daily life activities.

NCT ID: NCT04172415 Enrolling by invitation - Conscious Sedation Clinical Trials

Current Procedural Sedation Practices in a Canadian Community Emergency Department

Start date: November 30, 2019
Phase:
Study type: Observational

To review current Emergency Department procedural sedation practices in the community hospital setting and the associated drugs used (class of anesthetic and mode of administration). The ultimate goal of this investigation is to determine the need for a new analgesic/anesthesia drug and to compare the outcomes of a new drug within the same community Emergency Department setting. In particular, this may present a future opportunity to evaluate Penthrox (methoxyflurane) as a viable alternative for procedural sedation and analgesia in Canadian Emergency Departments.

NCT ID: NCT04172077 Completed - Type1diabetes Clinical Trials

Self Efficacy Levels, Attachment Style and Resiliency of Youth With Type 1 Diabetes

Start date: September 18, 2019
Phase:
Study type: Observational

This project will assess self-efficacy levels(SE) ,resiliency and attachment style of adolescent with type 1 diabetes and their caregivers.SE and attachment style of patients and parents will be compared with each other as well as correlated with diabetes management as assessed by A1C and self inventory scale.

NCT ID: NCT04171830 Enrolling by invitation - Screening Clinical Trials

Clinical Surveillance Tool to Screen for Unmet Palliative Needs Among Patients in the Final Year of Life

HOMR
Start date: June 17, 2019
Phase: N/A
Study type: Interventional

One of the most important obstacles to improving end-of-life care is the inability of clinicians to reliably identify those who are approaching the end-of-life. Every aspect of a palliative approach to care - screening for unmet needs, treating symptoms, discussing goals of care, and developing a palliative management plan - depends on the reliable and accurate identification of patients with palliative needs. The investigators developed an accurate and reliable mortality prediction tool that automatically identifies patients in hospital at elevated risk of death in the coming year. In previous studies it has been shown that these patients also frequently have unmet palliative care needs at the time they are identified by the tool. This tool has been demonstrated feasible, acceptable to patients and providers, and effective for changing physician behaviour in an inpatient clinical context. In this project, this tool is implemented as part of an integrated knowledge translation project to facilitate reliable and timely identification of unmet palliative needs across multiple hospitals with different clinical settings and contexts. The investigators have partnered with 12 hospitals to improve the quality of palliative and end-of-life care provided to patients and families. With each partner site the investigators will develop a comprehensive implementation plan, including stakeholder engagement, education, and feedback. Process measures will be collected at each site to determine whether the tool was effective for promoting the identification and documentation of unmet palliative needs. Patients who were identified by the tool will also be followed over time to collect outcome and impact measures to see if their end-of-life care was affected by the intervention compared to control groups.

NCT ID: NCT04171661 Active, not recruiting - Clinical trials for Epidermolysis Bullosa Dystrophica

Self-Assembled Skin Substitute for the Treatment of Epidermolysis Bullosa

SASS
Start date: December 10, 2019
Phase: Early Phase 1
Study type: Interventional

Single patient study. Patient diagnosed with dystrophic epidermolysis bullosa presenting chronic open wounds that are not responding to dressings, topical preparations (antimicrobials, antibiotics) and systemic agents (anti-inflammatory antibacterials). The Self-Assembled Skin Substitutes will be used to cover wounds.

NCT ID: NCT04171492 Recruiting - Clinical trials for Non-small Cell Carcinoma

Nodify XL2 Classifier Clinical Utility Study in Low to Moderate Risk Lung Nodules

ALTITUDE
Start date: December 18, 2020
Phase:
Study type: Observational

This study evaluates the how addition of the Nodify XL2 test result impacts the clinical management of newly identified solid lung nodules assessed as low to moderate risk of cancer.

NCT ID: NCT04171466 Completed - Clinical trials for Antibiotic-associated Diarrhea

Metagenomic and Metabolomic Reconstitution of Gut Microbiota After Broad Spectrum Antibiotic Therapy

Start date: August 12, 2020
Phase: N/A
Study type: Interventional

In the United States, healthcare providers prescribe over 270 million antibiotic prescriptions each year. While antibiotics have transformed medicine and methods of treating life-threatening bacterial infection, broad spectrum antibiotics also induce disruption of resident gut microbial communities by altering both composition and function. This disruption of microbial community dynamics has been demonstrated at the taxonomic level, yet the extent of functional disruptions to microbial metabolic output and host cells remains understudied in humans. This study explores the impact of a broad spectrum antibiotic cocktail on microbial communities throughout the gastrointestinal tract, and the impact of a defined, multi-strain consortia of probiotic organisms following antibiotic exposure.